Business Context and Reporting Period
This Form 8-K was filed by Inpixon (referred to as XTI Aerospace, Inc. in metadata) on August 9, 2017. The report details a material definitive agreement entered into on the same date regarding the exercise of outstanding warrants and the issuance of new warrants.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $328,715.70 from the exercise of warrants.
- Shares Issued: Up to 1,095,719 shares of Common Stock.
- Exercise Price Adjustment: Reduced from $1.325 per share to $0.30 per share.
- Additional Warrants: Issued for an equal number of shares (1,095,719) at an exercise price of $0.55 per share.
- Use of Proceeds: General working capital, payment of outstanding debt, and trade payables.
- Transaction Costs: 7% cash commission paid to Aegis Capital Corp.
Material Changes and Agreements
The Company amended its Warrant Agency Agreement to significantly lower the exercise price to facilitate the transaction. Concurrently, the Company secured a waiver and consent from Hillair Capital Investments L.P. to issue securities below the $7.05 per share price floor previously established in Hillair's 8% Senior Convertible Debenture agreement.
Outlook, Risks, and Contingencies
- Registration Status: The Additional Warrants were issued unregistered under Section 4(a)(2) and Rule 506 of Regulation D, relying on the accredited investor status of the holders.
- Cashless Exercise: If no effective registration statement is available six months post-issuance, holders may exercise Additional Warrants on a cashless basis.
- Ownership Limitations: Exercise is restricted if it would cause a holder to beneficially own more than 4.99% of outstanding shares (adjustable up to 9.99% upon notice).
- Nasdaq Compliance: Issuance of Additional Warrant shares is capped at 1,298,281 shares unless shareholder approval is obtained for issuances exceeding 19.99% of outstanding stock or a change of control.
Investor Verification Checklist
- Verify the effective date and status of the Form S-1 Registration Statement (333-218173) referenced for the Exercised Shares.
- Confirm the total number of outstanding shares post-transaction to assess dilution impact relative to the 19.99% Nasdaq threshold.
- Review the full text of the Hillair Waiver (Exhibit 10.2) to understand any remaining covenants or restrictions on future financing.
- Monitor the Company's ability to maintain an effective registration statement for the resale of Additional Warrant shares to avoid cashless exercise scenarios.